From Contracts to Ownership, in a Single Fiscal Year
Alibaba's fiscal 2018 (ended March 31, 2018) results, covered separately, show a strong operating year clouded by two large, offsetting non-cash items. Underneath that accounting story is a structural one this post covers on its own: this is the year Alibaba stopped merely holding stakes and contractual arrangements in its own ecosystem and started buying outright control of them.
| Entity | Prior stake | New stake | Mechanism | Value disclosed |
|---|---|---|---|---|
| Cainiao Network | ~47% (equity method) | ~51% (consolidated), Oct 2017 | Cash subscription for newly issued shares | US$803M / RMB5,322M cash; RMB22,442M ($3,578M) non-cash remeasurement gain |
| Ele.me | ~27% (joint investment vehicle with Ant Financial) | Consolidated, controlling shareholder, May 2018 | Joint vehicle bought out all outstanding shares it didn't already own | US$5.5 billion total acquisition consideration |
| Alibaba Health | 46% | 48% (Jan 2018); ~56% agreed (May 2018, subsequent event) | Jan 2018: cash purchase of newly issued shares. May 2018: asset-for-shares transfer | HK$1,770M (RMB1,469M) cash; HK$10.6 billion agreed asset transfer |
| Ant Financial | 37.5% perpetual profit share (no equity) | 33% direct equity (pending regulatory approval) | 2018 SAPA Amendment swaps profit-share/IPO-payment rights for equity, self-funded via IP and asset transfer from Ant Financial to Alibaba | Not disclosed as a cash price; self-funding mechanism only |
Four moves happened inside twelve months. Cainiao Network, the logistics affiliate Alibaba had held as an equity-method investment since 2013, crossed 50% ownership in October 2017 via an $803 million cash subscription and was fully consolidated. Ele.me, previously a joint co-investment alongside Ant Financial, was completely bought out by their shared investment vehicle in May 2018, making Alibaba its controlling shareholder. Alibaba Health's effective ownership climbed from 46% to 48% during the year, with a further agreed move to roughly 56% just after fiscal year-end. And the single largest structural move of the year: in February 2018, Alibaba agreed to give up the perpetual 37.5% profit-share arrangement it had held with Ant Financial since 2014 - a genuinely unusual structure this publication flagged as far back as the FY2015 post - in exchange for a direct 33% equity stake in Ant Financial, funded entirely by payments from Ant Financial itself. The company that spent three years collecting a growing royalty from a business it didn't own is, this year, buying its way into owning a third of it.
The Prescription
Get genuinely ahead of the SEC's consolidation-practices inquiry rather than just continuing to "voluntarily" cooperate with it. The inquiry, open since early 2016, covers Alibaba's "prior practice of accounting for Cainiao Network as an equity method investee" - and fiscal 2018 is the exact year that practice changed, producing a RMB22,442 million non-cash gain the SEC now has a live, current transaction to examine instead of a hypothetical one. Two more years of "voluntary" document production on a subject the company itself just made materially larger isn't the same as resolving what the SEC is actually asking.
What Alibaba should stop doing: growing the Simon Xie related-party loan and the Alibaba Health stake-building through asset-for-shares swaps without ever explaining, in its own words, why either arrangement needs to keep expanding. The Xie loan grew from RMB749 million to RMB1,137 million this year (+51.8%) - the third straight year it has moved in only one direction since being flagged as unusual in the FY2015 post. Alibaba Health's ownership climb (38% → 46% → 48% → ~56% pending) has been funded almost entirely by Alibaba routing its own operating businesses into a subsidiary it already controls, in exchange for more of that subsidiary's stock. Neither arrangement is illegal or even necessarily bad for shareholders, but a pattern that only ever grows, never gets explained, and keeps surfacing in a footnote instead of a strategic rationale is exactly the kind of thing that turns routine related-party activity into the specific thing regulators start asking about - which is precisely what happened to the Cainiao consolidation this year.
Beyond the Usual
The SEC's still-open inquiry now has a live example of exactly what it's asking about
The SEC inquiry flagged in the FY2016 and FY2017 posts remains open more than two years after it began, and this filing confirms its scope includes Alibaba's "prior practice of accounting for Cainiao Network as an equity method investee" - the exact accounting treatment that changed in October 2017, when Alibaba's cash subscription pushed its stake past 50% and triggered full consolidation, generating a RMB22,442 million ($3,578 million) non-cash, non-taxable gain. Nothing about this transaction is disclosed as improper, and Alibaba states plainly that it continues cooperating and providing documents voluntarily. But a regulator specifically scrutinizing how a company accounts for transitions between equity-method and consolidated treatment of Cainiao, in the same fiscal year that exact transition produced a multi-billion-dollar gain, is not a coincidence a reader should read past without noting - the inquiry that's been "still open" for three consecutive annual reports just became more consequential, not less.
The gain itself is what a step acquisition (the accounting term for gaining control of an investee you already partly owned) produces almost mechanically. Under US GAAP, once a step acquisition crosses the consolidation threshold, the entire prior stake - not just the newly purchased shares - gets remeasured to fair value, and the difference between that fair value and its old equity-method carrying amount is booked as a one-time non-cash gain. The 20-F's purchase-price allocation for Cainiao spells out exactly this: the US$803 million (RMB5,322 million) cash subscription for newly issued shares only bought Alibaba a few points of additional ownership (from ~47% to ~51%), but the total "purchase price" recognized for accounting purposes was RMB33,657 million - RMB5,322 million of actual new cash plus RMB28,335 million representing the fair value assigned to the pre-existing ~47% stake Alibaba already held. That RMB28,335 million revaluation, net of the stake's old book value, is where the RMB22,442 million gain came from. This is precisely the mechanic regulators scrutinize in consolidation-timing questions: a company that controls when it crosses the 50% line has real discretion over when a multi-billion-dollar non-cash gain lands on its income statement, even though no economic transaction beyond the incremental share purchase actually occurred that year. Cainiao itself was no small logistics footnote by this point - its network of 15 strategic express-courier partners employed over 1.9 million delivery personnel across more than 700 Chinese cities and 31 provinces, operating over 200,000 hubs and sorting stations, and enabled delivery of 20.6 billion packages originating from Alibaba's China retail marketplaces during fiscal 2018. Once consolidated in mid-October 2017, Cainiao's logistics-services revenue contributed RMB6,759 million ($1,078 million) to Alibaba's core-commerce segment for the partial year - the filing does not break out what a full twelve months of Cainiao revenue would have been on a standalone basis.
Alibaba is trading a growing royalty stream for an equity stake funded by the counterparty itself
Royalty and profit-share income Alibaba recognized from Ant Financial grew 65.1% this year, from RMB2,086 million to RMB3,444 million ($549 million) - continuing the reversal last year's post flagged after a prior-year dip. In February 2018, in the middle of that growth, Alibaba agreed to give the entire arrangement up: the 2018 amendment to its 2014 agreement with Ant Financial (the "2018 SAPA Amendment") replaces the perpetual 37.5%-of-pretax-income profit share (and the associated right to a one-time payment of 37.5% of Ant Financial's equity value on a future IPO) with a direct 33% equity stake in Ant Financial, to be issued once Chinese regulatory approval is obtained. The mechanics are notably circular: the consideration Alibaba owes for that 33% stake "will be fully funded by payments from Ant Financial and its subsidiaries to us in consideration for certain intellectual property and assets that we will transfer" at closing - meaning Ant Financial is effectively financing Alibaba's purchase of Ant Financial equity, with no separate cash outlay from Alibaba itself. The filing does not disclose a dollar valuation for Ant Financial or for the 33% stake - no implied enterprise or equity value figure appears anywhere in this 20-F, only the structural terms of the swap - so any headline "Ant Financial is worth $X" number circulating from this period comes from outside sources, not this filing. Trading a growing royalty for direct equity ownership in one of China's most valuable private fintech companies is very plausibly the better long-term trade for Alibaba's shareholders. But the deal remains only an agreement as of this filing - contingent on PRC regulatory approval that hadn't yet arrived - and the self-funding structure is unusual enough to be worth tracking through to actual closing rather than treating as done. It's worth noting that it still hadn't closed a year later either: the FY2019 post's own valuation scenarios explicitly treat "the Ant Financial swap eventually closes" as a bull-case assumption rather than a settled fact, with the alternative - the swap unwinding back to the old profit-share structure - still live enough to appear in that post's bear case.
Two related-party arrangements flagged in prior posts kept growing, without new explanation
The Simon Xie related-party loan - flagged as unusual when it was a standby facility in the FY2015 post and first drawn to RMB749 million by FY2017 - grew again this year, to RMB1,137 million ($181 million), a 51.8% increase. Separately, Alibaba's effective equity ownership of its controlled healthcare affiliate Alibaba Health - listed on the Hong Kong Stock Exchange and engaged in self-operated healthcare product sales, e-commerce platform services, tracking services, and other innovation healthcare-related services in the PRC (in plain terms: an online pharmacy and healthcare-services platform, the "flagship vehicle" Alibaba states it wants for its digital-health strategy) - already raised from roughly 38% to 46% via the Tmall health-food asset transfer covered in last year's post, climbed further this year: to 48% via a HK$1,770 million (RMB1,469 million) cash purchase of approximately 442 million newly issued ordinary shares in January 2018, and (per a subsequent-events disclosure in this same filing) to an agreed ~56% via a further HK$10.6 billion transfer of Alibaba's medical-device, adult-product, and Tmall healthcare-services businesses - to be settled through roughly 1.8 billion newly issued Alibaba Health shares - in May 2018, just after fiscal year-end. Neither arrangement is new this year, and neither is disclosed as improper. But three consecutive annual reports now show both moving in only one direction - more owed, more owned - without Alibaba ever stating, in its own words, what the end state or strategic logic is meant to be.
The buyout that erased a joint venture: Ele.me goes from co-investment to full subsidiary
Ele.me (whose name means "Are you hungry?" in Chinese) was, as of March 31, 2018, a leading on-demand food-delivery and local-services platform covering over 670 cities in China - the same food-delivery category as Meituan, which this publication covers separately. Alibaba's path into it followed the identical "start as a minority co-investor, buy out control later" pattern as Cainiao: in March 2016, Alibaba and Ant Financial jointly committed US$1,250 million to a joint investment vehicle subscribing for Ele.me preferred shares, leaving Alibaba with roughly a 20% fully-diluted interest; further joint investments in April and August 2017 (Alibaba's share: US$864 million / RMB5,824 million) took Alibaba's effective interest to approximately 27%, still accounted for under the cost method since the preferred shares weren't considered in-substance common stock. In May 2018, that same joint investment vehicle completed the acquisition of all of Ele.me's remaining outstanding shares for a total consideration of US$5.5 billion, making Alibaba the controlling shareholder. Unlike Cainiao's cash-subscription route into majority ownership, this was a full buyout of the minority holders rather than a dilution-driven crossing of the 50% line - the filing states the accounting for this business combination, including any resulting gain, had not yet been finalized as of this annual report's issuance. The strategic logic Alibaba states plainly: deepen Ele.me's integration into its ecosystem and advance its "New Retail" strategy of a seamless online-offline consumer experience in local services - directly extending the same contractual-to-ownership pattern already playing out with Cainiao and Alibaba Health.
A structural change to how the VIEs are held, aimed at reducing key-man risk
Alibaba disclosed a "VIE Structure Enhancement" this year, targeted for completion across most of its variable interest entities in 2019: replacing direct personal ownership of VIE equity by Jack Ma and Simon Xie (the structure in place since this company's earliest public filings) with ownership through PRC limited liability companies and limited partnerships, held indirectly by a wider group of Alibaba Partnership members and management who are PRC citizens. The company states the explicit purpose is reducing "key man and succession risks" from having two named individuals as the direct legal owners of businesses core to Alibaba's China operations - a genuine structural improvement to a governance question every reader of this company's VIE disclosures should care about, not a criticism of how it was previously held.
Alibaba Group Holding Limited's Form 20-F annual report for the fiscal year ended March 31, 2018, filed with the U.S. Securities and Exchange Commission. Financial results for the same period are covered separately in this publication's fiscal 2018 earnings post.